RUNX1 and acute lymphoblastic leukemia: For instance, BCR–ABL1 fusion-gene-guided diagnosis and targeted therapy with imatinib resulted in an improvement in 5-year disease-free survival (DFS) of 70% [6]; moreover, other fusion genes, including rearranged KMT2A, ETV6–RUNX1, DUX4-IGH, and TCF3–PBX1 play important roles in the management of ALL.